Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Non-Current Assets (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Non-Current Assets data on record, last reported at $8.2 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 7.9% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $33.3 million, up 120.33%, while the annual FY2024 figure was $7.9 million, 178.49% up from the prior year.
  • Non-Current Assets reached $8.2 million in Q3 2025 per COEP's latest filing, down from $8.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $75.8 million in Q1 2022 and bottomed at $2.2 million in Q2 2024.
  • Average Non-Current Assets over 5 years is $23.0 million, with a median of $7.9 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: crashed 95.16% in 2023, then surged 284.9% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $4.6 million in 2021, then dropped by 13.35% to $4.0 million in 2022, then decreased by 29.0% to $2.8 million in 2023, then surged by 178.49% to $7.9 million in 2024, then rose by 4.24% to $8.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $8.2 million in Q3 2025, $8.5 million in Q2 2025, and $8.8 million in Q1 2025.